Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Explore practical smart money moves that can elevate your financial situation in everyday life. Start making informed choices now.
21,657 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Deed theft and fraudulent lien schemes are on the rise, quietly threatening homeowners. This guide breaks down how th...
A private Dallas developer secures a government-backed funding package to build a Gulf of Mexico deepwater oil termin...
Curious about reliable income from your stock holdings without chasing risky growth? This guide explains what Fidelit...
The crypto world is buzzing about XRP and a potential 90% plunge. This article breaks down the history, risk factors,...
A new forecast from microsoft leading copilot predicts XRP could reach as high as $15 by end-2026 if regulatory clari...
Gen Z entrepreneurs are using AI tools to launch startups faster. A new industry report highlights AI’s growing role ...
Traders are watching Ripple’s payments push and regulatory tones as an AI model’s no-guardrails forecast for XRP by 2...
A robotics company is shipping revenue today with a $22 billion backlog, turning heads in a market chasing autonomous...
A sharp weekly drain in Bitcoin ETF products highlights a split in investor demand. While BTC outflows led the pack, ...
A bipartisan push introduces the American Reserve Modernization Act to create a federal Bitcoin reserve and a Digital...
Regulators are leaning into nonprofit oversight, boosting enforcement actions even as verified cases of nonprofit fra...